Johnson & Johnson (JNJ) said Tuesday that investigational nipocalimab has received fast track designation from the US Food and Drug Administration for the treatment of adult patients with moderate to severe Sjogren's disease.
This comes after the investigational therapy was granted breakthrough therapy designation late last year, the company said.
The company said its mid-stage study from last year showed a greater than 70% relative average improvement in systemic disease activity at the 24th week when compared to placebo and IgG reductions of more than 77%.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.